| Year |
Citation |
Score |
| 2024 |
Zhang C, Liu Y, Jiang J, Chen C, Duan Z, Su H, Wang S, Tian B, Shi Y, Xiang R, Luo Y. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis. Theranostics. 14: 2757-2776. PMID 38773982 DOI: 10.7150/thno.94537 |
0.33 |
|
| 2024 |
Wu W, Li H, Chen W, Hu Y, Wang Z, She W, Huang L, Liu Y, Jiang P. CAR T Cell Membrane Camouflaged Nanocatalyst Augments CAR T Cell Therapy Efficacy Against Solid Tumor. Small (Weinheim An Der Bergstrasse, Germany). e2401299. PMID 38746996 DOI: 10.1002/smll.202401299 |
0.404 |
|
| 2024 |
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Maharjan CK, Patel UM, De U, Carelock ME, Tithi TI, Li X, Shaffer DR, Guertin KR, et al. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. The Journal of Experimental Medicine. 221. PMID 38334978 DOI: 10.1084/jem.20231519 |
0.333 |
|
| 2024 |
Li Y, Yuan Z, Wang L, Yang J, Pu P, Le Y, Chen X, Wang C, Gao Y, Liu Y, Wang J, Gao X, Li Y, Wang H, Zou C. Prolyl isomerase Pin1 sculpts the immune microenvironment of colorectal cancer. Cellular Signalling. 111041. PMID 38199598 DOI: 10.1016/j.cellsig.2024.111041 |
0.453 |
|
| 2024 |
Mathioudaki A, Wang X, Sedloev DN, Huth R, Kamal A, Hundemer M, Liu Y, Vasileiou S, Lulla PD, Müller-Tidow C, Dreger P, Luft T, Sauer T, Schmitt M, Zaugg JB, et al. The remission status of AML patients post alloSCT is associated with a distinct single-cell bone marrow T cell signature. Blood. PMID 38197505 DOI: 10.1182/blood.2023021815 |
0.403 |
|
| 2023 |
Wang K, Zhang X, Cheng Y, Qi Z, Ye K, Zhang K, Jiang S, Liu Y, Xiao Y, Wang T. Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy. Journal of Medicinal Chemistry. PMID 38109261 DOI: 10.1021/acs.jmedchem.3c01534 |
0.363 |
|
| 2023 |
Jin S, Liu Y, Zhang Y, Zhou F, You L, Zhang J. Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting. Therapeutic Advances in Chronic Disease. 14: 20406223231215701. PMID 38058395 DOI: 10.1177/20406223231215701 |
0.332 |
|
| 2023 |
Yin X, Liu Y, Sun J, Tong H, Meng H, You L. Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting. Therapeutic Advances in Chronic Disease. 14: 20406223231213251. PMID 38028949 DOI: 10.1177/20406223231213251 |
0.314 |
|
| 2023 |
Li Y, Liu Y, Kang Z, Guo J, Liu N. Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses. Scientific Reports. 13: 19563. PMID 37949863 DOI: 10.1038/s41598-023-44028-3 |
0.331 |
|
| 2023 |
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Patel UM, Li X, Shaffer D, Guertin KR, Moser E, Smalley KS, Zhou D, Zheng G, et al. Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer Immunotherapy. Biorxiv : the Preprint Server For Biology. PMID 37609171 DOI: 10.1101/2023.08.09.552650 |
0.302 |
|
| 2023 |
Li H, Yang X, Wang Z, She W, Liu Y, Huang L, Jiang P. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming. Acs Nano. 17: 11749-11763. PMID 37319120 DOI: 10.1021/acsnano.3c02592 |
0.328 |
|
| 2023 |
Zhang G, Lan B, Zhang X, Lin M, Liu Y, Chen J, Guo F. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells. Journal For Immunotherapy of Cancer. 11. PMID 37164450 DOI: 10.1136/jitc-2022-006483 |
0.376 |
|
| 2023 |
Liu S, Xiang Y, Wang B, Gao C, Chen Z, Xie S, Wu J, Liu Y, Zhao X, Yang C, Yue Z, Wang L, Wen X, Zhang R, Zhang F, et al. USP1 promotes the aerobic glycolysis and progression of T-cell acute lymphoblastic leukemia via PLK1/LDHA axis. Blood Advances. PMID 36912760 DOI: 10.1182/bloodadvances.2022008284 |
0.339 |
|
| 2023 |
Liu Y, Li N, Jiang W, Geng Q. [Recent Progress of Nano-drug Combined with Chimeric Antigen Receptor T Cell
Therapy in the Treatment of Soild Tumors]. Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer. 26: 59-65. PMID 36792082 DOI: 10.3779/j.issn.1009-3419.2023.102.02 |
0.31 |
|
| 2023 |
Quezada LK, Jin W, Liu YC, Kim ES, He Z, Indralingam CS, Tysl T, Labarta-Bajo L, Wehrens EJ, Jo Y, Kazane KR, Hattori C, Zuniga EI, Yeo GW, Chang JT. Early transcriptional and epigenetic divergence of CD8+ T cells responding to acute versus chronic infection. Plos Biology. 21: e3001983. PMID 36716323 DOI: 10.1371/journal.pbio.3001983 |
0.337 |
|
| 2022 |
Wang R, Hao M, Kou X, Sui B, Sanmillan ML, Zhang X, Liu D, Tian J, Yu W, Chen C, Yang R, Sun L, Liu Y, Giraudo C, Rao DA, et al. Apoptotic vesicles ameliorate lupus and arthritis via phosphatidylserine-mediated modulation of T cell receptor signaling. Bioactive Materials. 25: 472-484. PMID 37056273 DOI: 10.1016/j.bioactmat.2022.07.026 |
0.341 |
|
| 2022 |
Lin YH, Duong HG, Limary AE, Kim ES, Hsu P, Patel SA, Wong WH, Indralingam CS, Liu YC, Yao P, Chiang NR, Vandenburgh SA, Anderson TR, Olvera JG, Ferry A, et al. Small intestine and colon tissue-resident memory CD8 T cells exhibit molecular heterogeneity and differential dependence on Eomes. Immunity. PMID 36580919 DOI: 10.1016/j.immuni.2022.12.007 |
0.326 |
|
| 2022 |
Yin N, Liu Y, Weems C, Shreeder B, Lou Y, Knutson KL, Murray NR, Fields AP. Protein kinase Cι mediates immunosuppression in lung adenocarcinoma. Science Translational Medicine. 14: eabq5931. PMID 36383684 DOI: 10.1126/scitranslmed.abq5931 |
0.398 |
|
| 2022 |
Jiang Y, Yang Y, Hu Y, Yang R, Huang J, Liu Y, Wu Y, Li S, Ma C, Humphries F, Wang B, Wang X, Hu Z, Yang S. Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade. Cell Reports. 41: 111553. PMID 36288704 DOI: 10.1016/j.celrep.2022.111553 |
0.359 |
|
| 2022 |
Dai S, Liu Y, Zhao F, Wang H, Shao T, Xu Z, Shou L, Chen S, Zhang GC, Shu Q. Aqueous extract of Taxus chinensis var. mairei targeting CD47 enhanced antitumor effects in non-small cell lung cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 154: 113628. PMID 36058145 DOI: 10.1016/j.biopha.2022.113628 |
0.323 |
|
| 2022 |
Liu Y, Chen XQ, Wang F, Cheng B, Zhou G. Melatonin relieves Th17/CD4CD8 T cells inflammatory responses via nuclear-receptor dependent manner in peripheral blood of primary Sjögren's syndrome. International Immunopharmacology. 109: 108778. PMID 35537347 DOI: 10.1016/j.intimp.2022.108778 |
0.302 |
|
| 2022 |
Liu X, Jin S, Hu S, Li R, Pan H, Liu Y, Lai P, Xu D, Sun J, Liu Z, Gao Y, Zhao Y, Liu F, Xiao Y, Li Y, et al. Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma. Nature Communications. 13: 1158. PMID 35241665 DOI: 10.1038/s41467-022-28799-3 |
0.358 |
|
| 2022 |
Tian J, Dai SB, Jiang SS, Yang WY, Yan YQ, Lin ZH, Dong JX, Liu Y, Zheng R, Chen Y, Zhang BR, Pu JL. Specific immune status in Parkinson's disease at different ages of onset. Npj Parkinson's Disease. 8: 5. PMID 35013369 DOI: 10.1038/s41531-021-00271-x |
0.368 |
|
| 2022 |
Liu Y, Debo B, Li M, Shi Z, Sheng W, Shi Y. Author Correction: LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade. Nature Communications. 13: 263. PMID 34987158 DOI: 10.1038/s41467-021-27814-3 |
0.639 |
|
| 2021 |
Liu Y, Debo B, Li M, Shi Z, Sheng W, Shi Y. LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade. Nature Communications. 12: 6831. PMID 34819502 DOI: 10.1038/s41467-021-27179-7 |
0.65 |
|
| 2021 |
Gao Y, Liu Y, Sun L, Ouyang X, Zhu C, Qin X. MAD2L1 Functions As a Novel Diagnostic and Predictive Biomarker in Cholangiocarcinoma. Genetic Testing and Molecular Biomarkers. 25: 685-695. PMID 34788140 DOI: 10.1089/gtmb.2021.0122 |
0.131 |
|
| 2021 |
Liu Y, Wang S, Schubert ML, Lauk A, Yao H, Blank MF, Cui C, Janssen M, Schmidt C, Göllner S, Kleist C, Zhou F, Rahfeld JU, Sauer T, Schmitt M, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. International Journal of Cancer. PMID 34766343 DOI: 10.1002/ijc.33865 |
0.321 |
|
| 2021 |
Yang QY, Liu YJ, Ye X, Zhang L, Wang CD. The monitoring frequency of Interferon Gamma Release Assay for tuberculosis surveillance following Infliximab therapy in patients with Crohn's disease. Journal of Digestive Diseases. PMID 34240823 DOI: 10.1111/1751-2980.13032 |
0.053 |
|
| 2021 |
Dong L, Chen C, Zhang Y, Guo P, Wang Z, Li J, Liu Y, Liu J, Chang R, Li Y, Liang G, Lai W, Sun M, Dougherty U, Bissonnette MB, et al. The loss of RNA N-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8 T cell dysfunction and tumor growth. Cancer Cell. PMID 34019807 DOI: 10.1016/j.ccell.2021.04.016 |
0.368 |
|
| 2021 |
Jiang C, Wang K, Liu Y, Zhang C, Wang B. Application of Textile Technology in Tissue Engineering: A review. Acta Biomaterialia. PMID 33962070 DOI: 10.1016/j.actbio.2021.04.047 |
0.018 |
|
| 2021 |
Jiang C, Wang K, Liu Y, Zhang C, Wang B. Textile-based sandwich scaffold using wet electrospun yarns for skin tissue engineering. Journal of the Mechanical Behavior of Biomedical Materials. 119: 104499. PMID 33857876 DOI: 10.1016/j.jmbbm.2021.104499 |
0.028 |
|
| 2021 |
Jiang C, Wang K, Liu Y, Zhang C, Wang B. Using Wet Electrospun PCL/Gelatin/CNT Yarns to Fabricate Textile-Based Scaffolds for Vascular Tissue Engineering. Acs Biomaterials Science & Engineering. PMID 33821604 DOI: 10.1021/acsbiomaterials.1c00097 |
0.059 |
|
| 2021 |
Liu Y, Wu Y, Zhang P, Xu C, Liu Z, He C, Liu Y, Kang Z. CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes. Frontiers in Oncology. 11: 636870. PMID 33747959 DOI: 10.3389/fonc.2021.636870 |
0.406 |
|
| 2021 |
Sheng W, Liu Y, Chakraborty D, Debo B, Shi Y. Simultaneous Inhibition of LSD1 and TGF-B Enables Eradication of Poorly Immunogenic Tumors with anti-PD-1 Treatment. Cancer Discovery. PMID 33687985 DOI: 10.1158/2159-8290.CD-20-0017 |
0.677 |
|
| 2020 |
Jia L, Wu R, Han N, Fu J, Luo Z, Guo L, Su Y, Du J, Liu Y. and GG regulate the Th17/Treg balance in colitis via TLR4 and TLR2. Clinical & Translational Immunology. 9: e1213. PMID 33282294 DOI: 10.1002/cti2.1213 |
0.303 |
|
| 2020 |
Zhang M, Liu Y, Chen J, Chen L, Meng J, Yang C, Yin S, Zhang X, Zhang L, Hao Z, Chen X, Liang C. Single-cell multi-omics analysis presents the landscape of peripheral blood T-cell subsets in human chronic prostatitis/chronic pelvic pain syndrome. Journal of Cellular and Molecular Medicine. PMID 33124198 DOI: 10.1111/jcmm.16021 |
0.308 |
|
| 2020 |
Yang Q, Shi G, Chen X, Lin Y, Cheng L, Jiang Q, Yan X, Jiang M, Li Y, Zhang H, Wang H, Wang Y, Wang Q, Zhang Y, Liu Y, et al. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. Theranostics. 10: 8382-8399. PMID 32724476 DOI: 10.7150/thno.45391 |
0.361 |
|
| 2019 |
Zhang Y, Zhao Y, Shen J, Sun X, Liu Y, Liu H, Wang Y, Wang J. Nano-Enabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy. Nano Letters. PMID 30943039 DOI: 10.1021/acs.nanolett.8b04296 |
0.341 |
|
| 2019 |
Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, Huang X, Liu Y, Wang J, Dougherty U, Bissonnette MB, Shen B, Weichselbaum RR, Xu MM, He C. Anti-tumour immunity controlled through mRNA mA methylation and YTHDF1 in dendritic cells. Nature. PMID 30728504 DOI: 10.1038/S41586-019-0916-X |
0.325 |
|
| 2018 |
Shi G, Yang Q, Zhang Y, Jiang Q, Lin Y, Yang S, Wang H, Cheng L, Zhang X, Li Y, Wang Q, Liu Y, Wang Q, Zhang H, Su X, et al. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 30527756 DOI: 10.1016/j.ymthe.2018.11.010 |
0.369 |
|
| 2017 |
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, ... ... Liu Y, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet (London, England). PMID 28600132 DOI: 10.1016/S0140-6736(17)31266-7 |
0.306 |
|
| 2017 |
Fung-Leung WP, Edwards W, Liu Y, Ngo K, Angsana J, Castro G, Wu N, Liu X, Swanson RV, Wickenden AD. T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers. Plos One. 12: e0170102. PMID 28107393 DOI: 10.1371/journal.pone.0170102 |
0.376 |
|
| 2016 |
Xu Y, Liu Y, Yang C, Kang L, Wang M, Hu J, He H, Song W, Tang H. Macrophages transfer antigens to DCs by releasing exosomes containing dead cell-associated antigens partially through ceramide-dependent pathway to enhance CD4(+) T cell response. Immunology. PMID 27278624 DOI: 10.1111/imm.12630 |
0.304 |
|
| 2015 |
Yu N, Fu S, Xu Z, Liu Y, Hao J, Zhang A, Wang B. Synergistic antitumor responses by combined GITR activation and Sunitinib in metastatic renal cell carcinoma. International Journal of Cancer. Journal International Du Cancer. PMID 26239999 DOI: 10.1002/ijc.29713 |
0.314 |
|
| 2015 |
Liu Y, Zhang L, Zhu X, Wang Y, Liu W, Gong W. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway. Immunology. PMID 26194418 DOI: 10.1111/imm.12508 |
0.304 |
|
| 2014 |
Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee JY, Olshen RA, Weyand CM, Boyd SD, Goronzy JJ. Diversity and clonal selection in the human T-cell repertoire. Proceedings of the National Academy of Sciences of the United States of America. 111: 13139-44. PMID 25157137 DOI: 10.1073/Pnas.1409155111 |
0.319 |
|
| 2010 |
Ding G, Liu Y, An Y, Zhang C, Shi S, Wang W, Wang S. Suppression of T cell proliferation by root apical papilla stem cells in vitro. Cells, Tissues, Organs. 191: 357-64. PMID 20090301 DOI: 10.1159/000276589 |
0.336 |
|
| 2009 |
Yan B, Liu Y. The Nature of Increased Circulating CD4CD25Foxp3 T Cells in Patients with Systemic Lupus Erythematosus: A Novel Hypothesis. The Open Rheumatology Journal. 3: 22-4. PMID 19590592 DOI: 10.2174/1874312900903010022 |
0.307 |
|
| 2009 |
Xu L, Liu Y, He X. Inhibitory effects of berberine on the activation and cell cycle progression of human peripheral lymphocytes. Cellular & Molecular Immunology. 2: 295-300. PMID 16274628 |
0.32 |
|
| 2008 |
Liu Y, Xu L, Jiang Y, Sun J, He X. Phenotypic and functional analysis of LCMV gp33-41-specific CD8 T cells elicited by multiple peptide immunization in mice revealed the up-regulation of PD-1 expression on antigen-specific CD8 T cells. Cellular & Molecular Immunology. 4: 431-7. PMID 18163954 |
0.36 |
|
| 2007 |
He XH, Jia QT, Li FY, Saltis M, Liu Y, Xu LH, Zha QB. CD8(+) T cells specific for both persistent and non-persistent viruses display distinct differentiation phenotypes but have similar level of PD-1 expression in healthy Chinese individuals. Clinical Immunology (Orlando, Fla.). 126: 222-34. PMID 17942371 DOI: 10.1016/j.clim.2007.08.021 |
0.424 |
|
| 2007 |
Xiao H, Huang B, Yuan Y, Li D, Han L, Liu Y, Gong W, Wu F, Zhang G, Feng Z. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo Clinical Cancer Research. 13: 1823-1830. PMID 17325342 DOI: 10.1158/1078-0432.Ccr-06-2154 |
0.352 |
|
| 2006 |
He XH, Zha QB, Liu Y, Xu LH, Chi XY. High frequencies cytomegalovirus pp65(495-503)-specific CD8+ T cells in healthy young and elderly Chinese donors: characterization of their phenotypes and TCR Vbeta usage. Journal of Clinical Immunology. 26: 417-29. PMID 16850281 DOI: 10.1007/s10875-006-9035-1 |
0.301 |
|
| 2006 |
Xu L, Liu Y, He X. Expression and purification of soluble human programmed death-1 in Escherichia coli. Cellular & Molecular Immunology. 3: 139-43. PMID 16696901 |
0.35 |
|
| Show low-probability matches. |